Viking Therapeutics, Inc. - Common Stock (VKTX)

The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a single session. The massive sell-off, which erased approximately $100 billion in market capitalization, was triggered

A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow.

Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing clinical data from its primary rival, Novo Nordisk (NYSE: NVO), which announced that its highly anticipated next-generation weight-loss drug,

COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated Phase 3 trial results for its next-generation obesity treatment, CagriSema. The data from the REDEFINE 4 study revealed that the drug,

Viking stock has plenty of room to run.

These biotech companies have catalysts ahead.

Never say never. There's certainly a mathematical path to that level, if the company navigates it correctly.

In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion market capitalization. This monumental achievement, finalized in early February 2026, marks a paradigm shift in how investors value

Viking should have plenty of news to share with investors this year.

The financial landscape shifted violently this week as the long-dormant Russell 2000 index (INDEXRUSSELL:RUT) staged a breathtaking 18% rally, marking its best single-week performance in decades. Triggered by a surprisingly soft Consumer Price Index (CPI) report released on Wednesday, the surge has ignited what analysts are calling "The Great

In a decisive shift for equity markets, the small-cap heavy Russell 2000 index outperformed its large-cap peers on Friday, February 13, 2026, as investors cheered a cooler-than-expected Consumer Price Index (CPI) report. The surge reflects a growing market consensus that the Federal Reserve may accelerate its rate-cutting cycle, providing much-needed

The company ended 2025 with $706 million in cash, which it said is enough to fund ongoing Phase 3 trials and maintenance data readouts.

Viking Therapeutics (NASDAQ:VKTX) stock is soaring on Thursday, extending the momentum it picked up in Wednesday's after‑hours session following the company's fourth‑quarter earnings release.

Viking (VKTX) Q4 2025 Earnings Call Transcript

The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity.

This stock has been known to soar after good news.

Could these two companies be biotech giants in the making?

The stock has climbed in the triple digits over the past three years.

The most recent gold rush in weight loss drugs isn't done just yet.

Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83 billion. The announcement, made during the company’s early February earnings call, marks a historic turning point in the pharmaceutical

In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a staggering 45% surge in full-year 2025 revenue, propelled by the insatiable global demand for its blockbuster treatments,

This pre-revenue biopharmaceutical stock is a home run swing worth taking.